Oncolytics Biotech Inc.

Oncolytics Biotech Inc. is a biotechnology company focused on the development of oncolytic viruses as potential therapeutics for use in a broad range of cancers. The company is conducting clinical studies using Reolysin, its proprietary formulation of the human reovirus, in some of the most prevalent forms of the disease including lung, colorectal and pancreatic cancers. Oncolytics' clinical program includes a number of human trials at a variety of stages including a phase 3 trial in head and neck cancers. The company has advanced its product manufacturing and intellectual property initiatives parallel to its clinical development program to support development of a commercial product.